<DOC>
	<DOCNO>NCT02410603</DOCNO>
	<brief_summary>The purpose study explore detection circulate tumor DNA , soluble immune marker , evaluation peripheral blood mononuclear cell ( PBMC ) .</brief_summary>
	<brief_title>Isolating Testing Circulating Tumor DNA Soluble Immune Markers During Course Treatment Lung Cancer</brief_title>
	<detailed_description>Our plan collect blood patient advance stage lung cancer schedule undergo systemic therapy . In study utilize novel technology circulate tumor DNA detection order evaluate presence patient lung cancer compare blood sample six time point . We obtain baseline blood collect blood five time point course patient 's chemotherapy treatment end treatment . These blood collection use detection soluble immune marker evaluation PBMCs .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Advanced ( nonresectable ) malignancy thorax Age &gt; 18 year old Willing able provide consent No prior history neoadjuvant therapy Age &lt; 18 year old Unable provide consent Patients hemoglobin le 10 g/dL ( minimize impact potential iatrogenic anemia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chemotherapy</keyword>
</DOC>